Onglyza

Onglyza

Onglyza is a DPP-4 inhibitor used to treat Americans that have Type 2 diabetes to control their blood glucose levels. Onglyza gained FDA authorization even with early concerns about the risk of cardiovascular issues from taking the drug. Though the FDA cleared the new diabetic drug, the department still had questions about the accuracy of the clinical trials and ordered AstraZeneca to perform a post-marketing study. AstraZeneca completed a 16,000-patient cardiovascular outcomes trial called SAVOR. The results of that trial were published in the New England Journal of Medicine and caused many Onglyza safety concerns.

The clinical trial showed that Onglyza patients had a 27% higher probability to be hospitalized for heart failure. The Onglyza trials also found a considerable rise in the risk of death overall. By waiting to perform the more all-inclusive testing of Onglyza after FDA-approval, AstraZeneca allowed thousands of patients to be needlessly exposed to heart failure and death risks.

Warning Signs of Heart Failure

According to the American Heart Association, the warning signs of heart failure are:

  • Shortness of breath
  • A persistent cough or wheezing
  • Swelling in the lower extremities or abdomen
  • Fatigue
  • Nausea
  • Diminished appetite
  • Impaired cognitive ability
  • Increased heart rate

Other Dangerous Side Effects of Onglyza

  • Pancreatic cancer
  • Thyroid cancer
  • Severe joint pain
  • Pancreatitis
  • Upper respiratory tract infection
  • Urinary tract infection
  • Severe allergic reactions
  • Hypoglycemia

If you or a loved one has taken Onglyza and suffered heart failure and/or death, you may have a case for compensation against AstraZeneca.

Please contact us at 706-235-7272 to schedule a free initial consultation. If you are unable to visit us at our office, we are happy to schedule an appointment at a time and place that is more convenient for you.